课题基金 / 基金详情

EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B

EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B
乙型肝炎拉米夫定持续时间反应的流行病学
批准号：
6263855
负责人：
IAN S GRIMM
金额：
$0.02万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6263855
关键词：
clinical research drug screening /evaluation hepatitis B hepatitis B virus group human subject human therapy evaluation lamivudine liver disorder chemotherapy relapse /recurrence serology /serodiagnosis virus DNA

项目摘要

项目成果

IAN S GRIMM的其他基金

相关文献

中文摘要
翻译
本研究的目的是评估拉米夫定治疗血清转化患者的反应持久性。该定义将基于实验室值。 如果患者发生活动性B型肝炎感染，本研究还将提供拉米夫定治疗。 早期的研究表明拉米夫定有降低血液中B型肝炎DNA水平的潜力。 这可能与对肝脏疾病和重症患者结局的积极影响相关。
英文摘要
The purpose of this study is to assess the durability of response in patients who have been treated with lamivudine and have seroconverted. This definition will be based on laboratory values. Should a patient develop active hepatitis B infection, this study will also provide lamivudine treatment. Early studies have shown that lamivudine has the potential to reduce the levels of hepatitis B DNA in the blood. This may correlate to a positive effect on the liver disease and outcome in seriously ill patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B
LAMIVUDINE AND INTRON A IN PATIENTS WITH CHRONIC HEPATITIS B